Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Transgene S.A.
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
May 27, 2026
Transgene’s Combined General Meeting of May 22, 2026
May 27, 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
May 24, 2026
Transgene Provides Business and Financial Update for Q1 2026
May 24, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
May 21, 2026
Availability of Transgene’s 2025 Universal Registration Document (URD)
May 21, 2026
Transgene to Participate in Upcoming Investor Meetings
May 20, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
May 20, 2026
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
May 19, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
May 19, 2026
1
2
Next Page
→